Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Primary objective of this open label, two-arm, multicenter, multinational, randomized trial
is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients
with acute leukemia in complete remission between a 10/10 HLA matched unrelated donor and a
haploidentical donor.
The hypothesis: Haploidentical stem cell transplantation with post cyclophosphamide induces a
stronger anti-leukemic activity in comparison to 10/10 HLA matched unrelated donor and
reduces the risk of relapse at 2 years after stem cell transplantation by 10%.
Phase:
Phase 2
Details
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Collaborators:
Clinical Trial Center North (CTC North GmbH & Co. KG) DKMS Stiftung Leben Spenden